KRAS and neoplasm: Except for UTE3, a primary tumor cell line characterized by a low TMB, the other four cell lines all harbored one or two alterations each in genes related to the RAS/MAPK pathway (i.e., the target of avutometinib) (Figure 1B) including a KRAS G13C alteration in UTE1 and a BRAF D594N alteration in UTE2.